Bogart Wealth LLC Takes Position in Insulet Co. (NASDAQ:PODD)

Bogart Wealth LLC acquired a new stake in Insulet Co. (NASDAQ:PODD - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 23,635 shares of the medical instruments supplier's stock, valued at approximately $6,170,000.

Several other large investors also recently added to or reduced their stakes in the stock. Baillie Gifford & Co. lifted its position in shares of Insulet by 20.7% in the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier's stock worth $529,669,000 after purchasing an additional 389,639 shares during the period. Mizuho Securities USA LLC lifted its position in shares of Insulet by 5,928.1% in the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier's stock worth $75,835,000 after purchasing an additional 320,416 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Insulet by 43.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier's stock worth $148,091,000 after purchasing an additional 193,839 shares during the period. Westfield Capital Management Co. LP lifted its position in shares of Insulet by 27.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier's stock worth $175,697,000 after purchasing an additional 163,388 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec bought a new position in shares of Insulet during the 3rd quarter worth approximately $16,342,000.

Insider Transactions at Insulet

In related news, CAO Lauren Budden sold 915 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares of the company's stock, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.47% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on PODD shares. Citigroup boosted their price objective on shares of Insulet from $283.00 to $310.00 and gave the stock a "buy" rating in a research note on Wednesday, December 11th. Canaccord Genuity Group boosted their price objective on shares of Insulet from $269.00 to $304.00 and gave the stock a "buy" rating in a research note on Monday, December 9th. JPMorgan Chase & Co. boosted their price objective on shares of Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a research note on Thursday, December 12th. Wells Fargo & Company upped their price target on shares of Insulet from $290.00 to $305.00 and gave the company an "overweight" rating in a research note on Wednesday, December 11th. Finally, Sanford C. Bernstein started coverage on shares of Insulet in a research note on Wednesday, November 6th. They set an "outperform" rating and a $300.00 price target on the stock. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $277.13.

Insulet Stock Performance

Shares of NASDAQ:PODD traded up $0.15 during midday trading on Tuesday, reaching $280.71. The company's stock had a trading volume of 662,395 shares, compared to its average volume of 532,819. The firm has a market capitalization of $19.69 billion, a PE ratio of 48.07, a P/E/G ratio of 3.61 and a beta of 1.23. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $289.46. The stock has a fifty day moving average of $272.17 and a 200 day moving average of $245.91. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.